Publication Name	World Journal of Diabetes
Manuscript ID	41790
Country	Japan

Received	2018-08-27 03:14
Peer-Review Started	2018-08-27 07:06
To Make the First Decision	2018-10-08 07:15
Return for Revision	2018-10-10 01:53
Revised	2018-10-15 07:22
Second Decision	2018-11-23 10:38
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2018-11-27 00:01
Articles in Press	2018-11-27 00:01
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-11-30 03:55
Publish the Manuscript Online	2018-12-14 01:19

ISSN	1948-9358 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Minireviews
Article Title	Effects of glucose-lowering agents on cardiorespiratory fitness
Manuscript Source	Invited Manuscript
All Author List	Hidetaka Hamasaki
ORCID	Author(s) ORCID Number Hidetaka Hamasaki http://orcid.org/0000-0002-0124-597X
Funding Agency and Grant Number
Corresponding Author	Hidetaka Hamasaki, MD, PhD, Doctor, Endocrinology and Metabolism, Internal Medicine, Hamasaki Clinic, 2-21-4 Nishida, Kagoshima 8900046, Japan. hhamasaki78@gmail.com
Key Words	Type 2 diabetes; Glucagon-like peptide l receptor agonist; Cardiorespiratory fitness; Exercise capacity; Metformin; Thiazolidinedione; Sodium-glucose cotransporter 2 inhibitors
Core Tip	Core tip: What is the most effective combination of drugs and exercise for the treatment of type 2 diabetes? It has become increasingly important for clinicians to prescribe drugs that reduce cardiovascular disease and mortality in addition to their glucose-lowering effects. This review summarized the current literature investigating the effect of glucose-lowering agents on cardiorespiratory fitness. Thiazolidinediones, sodium–glucose cotransporter 2 inhibitors, and glucagon-like peptide-l receptor agonists have the potential to improve cardiorespiratory fitness; however, further re­search will be needed to confirm.
Publish Date	2018-12-14 01:19
Citation	Hamasaki H. Effects of glucose-lowering agents on cardio­respiratory fitness. World J Diabetes 2018; 9(12): 230-238
URL	https://www.wjgnet.com/1948-9358/full/v9/i12/230.htm
DOI	https://dx.doi.org/10.4239/wjd.v9.i12.230

Full Article (PDF)	WJD-9-230.pdf
Full Article (Word)	WJD-9-230.doc
Manuscript File	41790-Review.docx
Answering Reviewers	41790-Answering reviewers.pdf
Audio Core Tip	41790-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	41790-Conflict-of-interest statement.pdf
Copyright License Agreement	41790-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	41790-Language certificate.pdf
Peer-review Report	41790-Peer-review(s).pdf
Scientific Misconduct Check	41790-Scientific misconduct check.pdf
Scientific Editor Work List	41790-Scientific editor work list.pdf